Ratings Immutep ADR Nasdaq

Equities

IMMP

US45257L1089

Real-time Estimate Cboe BZX Other stock markets 12:52:32 2024-05-20 EDT			5-day change	1st Jan Change
3.095 ^USD	+4.56%		+5.80%	+29.17%

05-17	Capital One Initiates Immutep at Overweight Rating With $10 Price Target	MT
05-15	Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
IMMUTEP ADR	+29.17%	362M	-
MODERNA, INC.	+42.59%	50.93B	B-
IQVIA HOLDINGS INC.	-0.38%	42.12B	B
LONZA GROUP AG	+49.62%	42.05B	A
CELLTRION, INC.	-7.20%	29.18B	C
ICON PUBLIC LIMITED COMPANY	+13.31%	26.02B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.15%	18.9B	B
BIO-TECHNE CORPORATION	+8.08%	13.21B	B+
UNITED THERAPEUTICS CORPORATION	+24.37%	12.17B	B+
MEDPACE HOLDINGS, INC.	+30.19%	12.16B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes